A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Clinical trial NCT01516918 · COMPLETED
Trial details
- NCT number
- NCT01516918
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-02-01
- Primary completion
- 2013-09-01
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.